CLARITY PHARMACEUTICALS LIMITED (CU6)
Share Price Analysis and Chart

11/08/2026

1

Speculative Buy

$6.40

125.35%

Bell Potter views Clarity Pharmaceuticals' latest Secure trial update as supportive, with seven patients achieving complete responses to 67Cu SARbisPSMA and encouraging PSA outcomes at the 8GBq dose.

Among patients in the expansion cohort, 63% recorded PSA reductions of at least -50%, despite participants having received extensive prior treatment and generally only two or three doses in the study.

The analyst also notes tolerability remains favourable, with adverse events predominantly mild and one patient experiencing temporary grade-three events.

Further Secure data are expected in 2H2026, while the broker anticipates first commercial revenue in calendar 2028 and notes FY26 cash of around $178m. Speculative Buy and the $6.40 valuation are unchanged.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -24.90 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -27.50 cents.

11/08/2026

1

Buy

$8.41

196.13%

Canaccord Genuity maintains a Buy rating for Clarity Pharmaceuticals with an $8.41 target price following a positive clinical update from the ongoing SECuRE trial assessing 67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer.

Evaluating the 8 GBq cohorts, robust prostate-specific antigen responses showed 63% of patients achieving a -50% decline and 26% reaching a -90% decline at the data cut-off.

The therapy achieved an 81% radiographic disease control rate amongst evaluable patients, including a 31% complete response rate, comparing favourably to benchmark competing treatments.

The analyst views the differentiated copper isotope chemistry as strategically positioned to fit within a broader oncology franchise, noting current share prices appear to assign zero value to the program.

Final results from the trial are expected in the first half of 2027 following the recruitment of eight additional patients and ongoing dosing cycles.